Dasatinib (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Dasatinib" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

4^th place

8^th place

2^nd place

5^th place

low place

607^th place

3,984^th place

2,156^th place

68^th place

28^th place

low place

34^th place

399^th place

169^th place

102^nd place

416^th place

1semanticscholar.org

11^th place

51^st place

14^th place

46^th place

low place

low place

447^th place

409^th place

archive.today

»NHS - Healthcare News«. nelm.nhs.uk. Arhivirano iz prvotnega spletišča dne 5. maja 2013. Pridobljeno 27. septembra 2011.

cbz.si

http://www.cbz.si/cbz/bazazdr2.nsf/Search?SearchView&Query=(%5BJENALISTI%5D=1)+(%5BSEZNAMUCINKNAZIV%5D=_dasatinib*)&SearchOrder=4&SearchMax=301 Centralna baza zdravil, vpogled: 19. 10. 2021

doi.org

Keating GM (Januar 2017). »Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia«. Drugs. 77 (1): 85–96. doi:10.1007/s40265-016-0677-x. PMID 28032244. S2CID 207489056.
Olivieri, A.; Manzione, L. (2007). »Dasatinib: a new step in molecular target therapy«. Annals of Oncology. 18 Suppl 6: vi42–vi46. doi:10.1093/annonc/mdm223. PMID 17591830.
Yurttaş NO, Eşkazan AE (2018). »Dasatinib-induced pulmonary arterial hypertension«. British Journal of Clinical Pharmacology. 84 (5): 835–845. doi:10.1111/bcp.13508. PMC 5903230. PMID 29334406.
Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, in sod. (Junij 2006). »The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants«. Cancer Research. 66 (11): 5790–7. doi:10.1158/0008-5472.CAN-05-4187. PMID 16740718.
Piscitani L, Sirolli V, Morroni M, Bonomini M (2020). »Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations«. International Journal of Molecular Sciences. 21 (14): e4878. doi:10.3390/ijms21144878. PMC 7402330. PMID 32664269.
Braun TP, Eide CA, Druker BJ (2020). »Response and Resistance to BCR-ABL1-Targeted Therapies«. Cancer Cell. 37 (4): 530–542. doi:10.1016/j.ccell.2020.03.006. PMC 7722523. PMID 32289275.

drugs.com

»Dasatinib«. The American Society of Health-System Pharmacists. Pridobljeno 8. decembra 2017.

europa.eu

ema.europa.eu

»Sprycel EPAR«. Evropska agencija za zdravila (EMA). Pridobljeno 28. aprila 2020. Članek vsebuje besedilo iz tega vira, ki je v javni domeni.

fda.gov

»Sprycel (dasatinib) and risk of pulmonary arterial hypertension«. U.S. Food and Drug Administration (FDA). 23. september 2011. Pridobljeno 28. aprila 2020. Članek vsebuje besedilo iz tega vira, ki je v javni domeni.

handle.net

hdl.handle.net

World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

nelm.nhs.uk

»NHS - Healthcare News«. nelm.nhs.uk. Arhivirano iz prvotnega spletišča dne 5. maja 2013. Pridobljeno 27. septembra 2011.

nih.gov

pubmed.ncbi.nlm.nih.gov

Keating GM (Januar 2017). »Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia«. Drugs. 77 (1): 85–96. doi:10.1007/s40265-016-0677-x. PMID 28032244. S2CID 207489056.
Olivieri, A.; Manzione, L. (2007). »Dasatinib: a new step in molecular target therapy«. Annals of Oncology. 18 Suppl 6: vi42–vi46. doi:10.1093/annonc/mdm223. PMID 17591830.
Yurttaş NO, Eşkazan AE (2018). »Dasatinib-induced pulmonary arterial hypertension«. British Journal of Clinical Pharmacology. 84 (5): 835–845. doi:10.1111/bcp.13508. PMC 5903230. PMID 29334406.
Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, in sod. (Junij 2006). »The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants«. Cancer Research. 66 (11): 5790–7. doi:10.1158/0008-5472.CAN-05-4187. PMID 16740718.
Piscitani L, Sirolli V, Morroni M, Bonomini M (2020). »Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations«. International Journal of Molecular Sciences. 21 (14): e4878. doi:10.3390/ijms21144878. PMC 7402330. PMID 32664269.
Braun TP, Eide CA, Druker BJ (2020). »Response and Resistance to BCR-ABL1-Targeted Therapies«. Cancer Cell. 37 (4): 530–542. doi:10.1016/j.ccell.2020.03.006. PMC 7722523. PMID 32289275.

ncbi.nlm.nih.gov

Yurttaş NO, Eşkazan AE (2018). »Dasatinib-induced pulmonary arterial hypertension«. British Journal of Clinical Pharmacology. 84 (5): 835–845. doi:10.1111/bcp.13508. PMC 5903230. PMID 29334406.
Piscitani L, Sirolli V, Morroni M, Bonomini M (2020). »Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations«. International Journal of Molecular Sciences. 21 (14): e4878. doi:10.3390/ijms21144878. PMC 7402330. PMID 32664269.
Braun TP, Eide CA, Druker BJ (2020). »Response and Resistance to BCR-ABL1-Targeted Therapies«. Cancer Cell. 37 (4): 530–542. doi:10.1016/j.ccell.2020.03.006. PMC 7722523. PMID 32289275.

semanticscholar.org

api.semanticscholar.org

Keating GM (Januar 2017). »Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia«. Drugs. 77 (1): 85–96. doi:10.1007/s40265-016-0677-x. PMID 28032244. S2CID 207489056.

termania.net

https://www.termania.net/slovarji/slovenski-medicinski-slovar/5510976/dasatinib?query=dasatinib&SearchIn=All Slovenski medicinski e-slovar, vpogled: 19. 10. 2021.

tga.gov.au

ebs.tga.gov.au

»Sprycel (Dasatinib)« (PDF). Therapeutic Goods Administration (TGA). Pridobljeno 18. julija 2020.